Extensively drug-resistant tuberculosis: A new face to an old pathogen

Annual Review of Medicine

Volumn 60, Issue , 2009, Pages 307-320

  Shenoi, Sheela ^a   Friedland, Gerald ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Multiple drug resistant tuberculosis (MDR TB); South Africa; TB HIV coinfection; Tugela Ferry; XDR TB

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGGRESSION; BODY FLUID; BONE MARROW SUPPRESSION; CONJUNCTIVITIS; CONTACT EXAMINATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSARTHRIA; DYSGLYCEMIA; ENDOCRINE DISEASE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH SURVEY; HEPATITIS; HEPATITIS A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; HYPOTHYROIDISM; INCIDENCE; INFECTION CONTROL; INJECTION SITE PAIN; IRRITABILITY; LIVER FAILURE; METALLIC TASTE; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RETROBULBAR OPTIC NEUROPATHY; REVIEW; RISK FACTOR; SEIZURE; SEIZURE THRESHOLD; SEROTONIN SYNDROME; SHORT COURSE THERAPY; SIDE EFFECT; SKIN DISCOLORATION; SPUTUM SMEAR; STEVENS JOHNSON SYNDROME; TASTE DISORDER; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; TREMOR; TUBERCULIN TEST; TUBERCULOSIS; VERTIGO; VESTIBULAR DISORDER;

EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; RISK FACTORS;

EID: 67650741785     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.60.053107.103955     Document Type: Review

References (68)

1. World Health Organization. 2008. Global tuberculosis control-surveillance, planning, financing: WHO report 2008.WHO/HTM/TB/2008. 393. http://www.who.int/tb/publications/2008/en/
2. Kazionny B,Wells CB, Kluge H, et al. 2001. Implications of the growing HIV-1 epidemic for tuberculosis control in Russia. Lancet 358:1513-14
3. Morozova I, Riekstina V, Sture G, et al. 2003. Impact of the growing HIV-1 epidemic on multidrugresistant tuberculosis control in Latvia. Int. J. Tuberc. Lung Dis. 7(9):903-6
4. Centers for Disease Control and Prevention. 2008. Trends in tuberculosis-United States, 2007.MMWR 57(11):281-85
5. Pyle M. 1947. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc. Staff Meet. Mayo Clin. 22(21):465-72
6. British Medical Research Council. 1948. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2:769-82
7. Rattan A, Kalia A, Ahmad N. 1998. Multidrug-resistant mycobacterium tuberculosis: molecular perspectives. Emerg. Infect. Dis. 4(2):195-210
8. Gandhi N, Moll A, Pawinski R, et al. 2006. Favorable outcomes of integration of TB and HIV treatment in rural South Africa: the Sizonqoba study. Presented at Int. AIDS Conf., 16th, Toronto
9. Gandhi NR, Moll A, Sturm AW, et al. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-80
10. Centers for Disease Control and Prevention. 2006. Revised definition of extensively drug-resistant tuberculosis. MMWR 55:1176
11. World Health Organization. 2008. Antituberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394. http://www.who.int/ tb/publications/2008/en/
12. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR 55:301-5
13. Partners in Health. 2003. The PIH guide to medical management of multidrug-resistant tuberculosis. http://www.pih.org/inforesources/ pihguide-dotstb.html
14. Rich ML. 2006. Diagnosis and treatment of multidrug-resistant tuberculosis. In Reichman & Hershfield's Tuberculosis: A Comprehensive, International Approach, ed. MC Raviglione. New York: Informa Healthcare. 3rd ed.
15. World Health Organization. 2006. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. http://www.who.int/tb/publications/2006/en/index.html
16. Friedland G. 2007. Tuberculosis, drug resistance and HIV/AIDS: triple threat. Curr. Infect. Dis. Rep. 9:252-61
17. Wells CD, Cegielski JP, Nelson LJ, et al. 2007. HIV infection and multidrug-resistant tuberculosis-the perfect storm. J. Infect. Dis. 196(Suppl.):86-107
18. Lutfey M, Della-Latta P, Kapur V, et al. 1996. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am. J. Respir. Crit. Care Med. 153(2):837-40
19. Ridzon R, Whitney CG, McKenna MT, et al. 1998. Risk factors for rifampin mono-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 157:1881-84
20. Munsiff SS, Joseph S, Ebrahimzadeh A, et al. 1997. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin. Infect. Dis. 25:1465-67
21. Peloquin CA, Nitta AT, Burman WJ, et al. 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30:919-25
22. Tappero JW, Bradford WZ, Agerton TB, et al. 2005. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis. 41:461-69
23. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. 2004. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 48:4473-75
24. Moodley P, Moll A, Shah NS, et al. 2007. Multi- and extensively drug-resistant Mycobacterium tuberculosis in KwaZulu Natal. Presented at Intersci. Conf. Antimicrobial Agents and Chemotherapy, 47th, Chicago
25. Kim H, Hwang SS, Kim HJ, et al. 2007. Impact of extensive drug resistance on treatment outcomes in non-HIV infected patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 45:1290-95
26. Weyer K, Lancaster J, Brand J, et al. 2004. Survey of Tuberculosis Drug Resistance in South Africa 2001-2002. South African Medical Research Council. http://www.sahealthinfo.org/tb/tbsurvey.htm
27. Lyepshina S. 2007. Association between multidrug-resistant tuberculosis and HIV status in the civilian and penitentiary sectors of Donetsk Oblast, Ukraine. Presented at Union World Conf. Lung Health, 38th, Cape Town, South Africa
28. Jeon CY, Hwang SH, Min JH, et al. 2008. Extensively drug resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin. Infect. Dis. 46:42-49
29. Andrews JR, Gandhi NR, Moll AP, et al. 2007. Clinical predictors of multidrug and extensively drug-resistant tuberculosis in Tugela Ferry, South Africa. Presented at UnionWorld Conf. Lung Health, 38th, Cape Town, South Africa
30. Moore DAJ, Evans CAW, Gilman RH, et al. 2006. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 355:1539-50
31. Perkins MD, Cunningham J. 2007. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J. Infect. Dis. 196(Suppl.):15-27
32. O'Brien R. 2007. New diagnostics for MDR and XDR-TB: What is in the pipeline? Presented at UnionWorld Conf. Lung Health, 38th, Cape Town, South Africa
33. Barnard M, Albert H, Coetzee G, et al. 2008. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177:787-92
34. World Health Organization. 2006. The Stop TB strategy. WHO/HTM/TB/2006.368. http://www. whqlibdoc.who.int/hq/2006/WHO HTM STB 2006.368 eng.pdf
35. Leimane V, Riekstina V, Holtz TH, et al. 2005. Clinical outcome of individualised treatment of multidrugresistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365:318-26
36. Chan ED, Laurel V, Strand MJ, et al. 2004. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 169:1103-9
37. Yew WW, Chan CK, Chau CH, et al. 2000. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 117(3):744-51
38. Törün T, Tahaoglu K, Özmen I, et al. 2007. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 11(9):979-85
39. Mitnick CD, Shin SS, Seung KW, et al. 2008. Comprehensive management of extensively drug resistant tuberculosis. N. Engl. J. Med. 359(6):563-74
40. Lalloo UG, Naidoo R, Ambaram A. 2006. Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr. Opin. Pulm. Med. 12:179-85
41. Andrews JR, Gandhi NR, Moll AP, et al. 2007. High mortality among patients with multidrug and extensively drug-resistant tuberculosis in rural South Africa. Presented at UnionWorld Conf. Lung Health, 38th, Cape Town, South Africa
42. Ahuja SD,Munsiff SS, Sharma S, et al. 2007. Clinical outcomes of extensively drug resistant tuberculosis patients in New York City. Presented at UnionWorld Conf. Lung Health, 38th, Cape Town, South Africa
43. O'Donnell MR, Pym A, Master I, et al. 2007. Clinical treatment outcomes and epidemiologic risk factors for extensive drug resistant tuberculosis patients on treatment in KwaZulu-Natal, South Africa. Presented at Union World Conf. Lung Health, 38th, Cape Town, South Africa
44. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348:119-28
45. Wei X, Liang X, Walley J, et al. 2008. Decentralising tuberculosis services from county tuberculosis dispensaries to township hospitals in China: an intervention study. Int. J. Tuberc. Dis. 12(5):538-47
46. Padayatchi N, Friedland G. 2008. Controlled decentralised management of multiple and extensively drug resistant tuberculosis (MDR&XDRTB): an alternate model of care. Int. J. Tuberc. Lung Dis. 12(8):978-80
47. McIlleron H, Meintjes G, Burman WJ, et al. 2007. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect. Dis. 196(Suppl.):63-75
48. Singh JA, Upshur R, Padayatchi N. 2007. XDR-TB in South Africa: no time for denial or complacency. PLoS Med. 4(1):e50. doi:10.1371/journal.pmed. 0040050
49. Padayatchi N, Friedland G. 2007. Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opin. Pharmacother. 8(8):1035-37
50. Farmer P, Léandre F, Mukherjee J, et al. 2001. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull. World Health Organ. 79(12):1145-51
51. Miti S. 2003. Integration of tuberculosis treatment in a community-based home care programme for persons living with HIV/AIDS in Ndola, Zambia. Int. J. Tuberc. Lung Dis. 7(Suppl.):92-98
52. Coetzee D, Hilderbrand K, Goemaere E, et al. 2004. Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop. Med. Int. Health 9(6):a11-15
53. Friedland G, Karim SA, Karim QA, et al. 2004. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin. Infect. Dis. 38(Suppl.):421-28
54. Jack C, Lalloo U, Karim QA, et al. 2004. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J. Acquir. Immune Defic. Syndr. 36:929-34
55. Friedland G, Harries A, Coetzee D. 2007. Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies. J. Infect. Dis. 196(Suppl.):114-23
56. World Health Organization & Stop TB Partnership. 2006. The global plan to stop TB 2006-2015. http://www.stoptb.org/globalplan/
57. World Health Organization. 2007. Tuberculosis infection control in the era of expanding HIV care and treatment. Addendum toWHOguidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. WHO/TB/99.269/2007. http://www.who.int/tb/publications/2007/en/ index.html
58. Bock NN, Jensen PA, Miller B, et al. 2007. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J. Infect. Dis. 196(Suppl):108-13
59. Escombe AR, Oeser CC, Gilman RH, et al. 2007. Natural ventilation for the prevention of airborne contagion. PLoS Med. 4(2):e68. doi:10.1371/journal.pmed.0040068
60. Moll A. 2007. Treatment of HIV-associated XDR TB patients. Presented at UnionWorld Conf. Lung Health, 38th, Cape Town, South Africa
61. Basu S, Andrews JR, Poolman EM, et al. 2007. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: a modeling study. Lancet 370:1500-7
62. Sturm AW. 2007. The role and value of molecular characterization of XDR-TB strains. Presented at Union World Conf. Lung Health, 38th, Cape Town, South Africa
63. Pillay M, Sturm AW. 2007. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45:1409-14
64. Onyebujoh PC, Ribeiro I, Whalen CC. 2007.Treatment options for HIV-associated tuberculosis. J. Infect. Dis. 196(Suppl.):35-45
65. Manosuthi W, Chottanapand S, Thongyen S, et al. 2006. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 43:42-46
66. Lawn SD, Myer L, Bekker LG, et al. 2006. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 20(12):1605-12
67. MitnickCD,CastroKG,HarringtonM,et al. 2007. Randomized trials to optimize treatment of multidrugresistant tuberculosis. PLoS Med. 4(11):e292 doi:10.1371/journal.pmed.0040292
68. Nunn P, Kibuga D, Gathua S, et al. 1991. Thiacetazone commonly causes cutaneous hypersensitivity reactions in HIV positive patients treated for tuberculosis. Lancet 337:627-30